Earnings History Data for BridgeBio Pharma, Inc. (BBIO) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

BridgeBio Pharma, Inc.

BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
10-08-2026	AH		BBIO	BridgeBio Pharma, Inc.	16,200	-0.78	-0.64	-0.95	BridgeBio Pharma GAAP EPS of -$0.78 misses by $0.19, revenue of $243.68M beats by $23.97M [8/10/2026 4:02 PM]	83.64	-1.03 (-1.22%)	87.07	2.40 (2.83%)	46.29 - 93.42	2,580,771	2,100,000	7,694
BridgeBio Pharma GAAP EPS of -$0.78 misses by $0.19, revenue of $243.68M beats by $23.97M [8/10/2026 4:02 PM] BridgeBio outlines three launches with first PDUFA set for November 27, 2026 and RECLAIM-HP readout in next 18 months [8/10/2026 8:59 PM]
07-05-2026	AH		BBIO	BridgeBio Pharma, Inc.	13,470	-0.84	-0.70	-0.88	BridgeBio Pharma GAAP EPS of -$0.84 misses by $0.16, revenue of $194.5M beats by $15.89M [5/7/2026 4:06 PM]	66.99	-0.46 (-0.68%)	67.00	-0.45 (-0.67%)	31.77 - 84.94	3,275,241	3,690,000	5,182
BridgeBio Pharma GAAP EPS of -$0.84 misses by $0.16, revenue of $194.5M beats by $15.89M [5/7/2026 4:06 PM] BridgeBio outlines $500M share repurchase as it targets P&L breakeven in 2027 [5/8/2026 11:32 AM]
24-02-2026	AH		BBIO	BridgeBio Pharma, Inc.	13,130	-1.00	-0.75	-1.31	BridgeBio Pharma GAAP EPS of -$1.00 misses by $0.33, revenue of $154.2M beats by $5.13M [2/24/2026 4:06 PM]	66.37	-1.95 (-2.85%)	70.47	2.16 (3.16%)	28.33 - 84.94	4,728,315	3,660,000	43,647
BridgeBio Pharma GAAP EPS of -$1.00 misses by $0.33, revenue of $154.2M beats by $5.13M [2/24/2026 4:06 PM] BridgeBio outlines transition to cash generation by 2028 with $600M profit target, driven by pipeline advances and Attruby growth [2/24/2026 7:28 PM]
29-10-2025	AH		BBIO	BridgeBio Pharma, Inc.	12,150	-0.95	-0.88	-0.86	BridgeBio Pharma GAAP EPS of -$0.95 misses by $0.06, revenue of $120.7M beats by $14.65M [10/29/2025 4:04 PM]	63.36	-3.27 (-4.90%)	66.10	-0.52 (-0.78%)	21.72 - 69.48	4,315,996	2,900,000	16,530
BridgeBio succeeds in late-stage encaleret study [10/29/2025 10:05 AM] BridgeBio Pharma GAAP EPS of -$0.95 misses by $0.06, revenue of $120.7M beats by $14.65M [10/29/2025 4:04 PM] BridgeBio targets 30%+ market share for Attruby while advancing late-stage pipeline and reporting $120.7M Q3 revenue [10/29/2025 10:57 PM] BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High [2025-10-29 07:04AM] BridgeBio chalks up another win for its rare disease research [2025-10-29 03:55AM] BridgeBio Pharma: Q3 Earnings Snapshot [2025-10-29 04:14PM]
05-08-2025	AH		BBIO	BridgeBio Pharma, Inc.	8,990	-0.95	-0.78	-1.02	BridgeBio Pharma GAAP EPS of -$0.95 misses by $0.11, revenue of $110.56M beats by $21.78M [8/5/2025 4:05 PM]	45.02	-4.19 (-8.51%)	44.50	-4.71 (-9.57%)	21.72 - 49.77	12,729,665	2,360,000	249,728
BridgeBio Pharma GAAP EPS of -$0.95 misses by $0.11, revenue of $110.56M beats by $21.78M [8/5/2025 4:05 PM] BridgeBio Pharma Inc (BBIO) Q2 2025: Everything You Need To Know Ahead Of Earnings [Aug-04-25 09:22AM]
29-04-2025	AH		BBIO	BridgeBio Pharma	6,827	-0.88	-0.95	0.00	BridgeBio Pharma GAAP EPS of -$0.88 beats by $0.05, revenue of $116.63M beats by $58.91M [4/29/2025 4:34 PM]	38.35	1.93 (5.30%)	38.61	2.19 (6.01%)	21.62 - 39.54	9,110,483	0	558,552
BridgeBio Pharma GAAP EPS of -$0.88 beats by $0.05, revenue of $116.63M beats by $58.91M [4/29/2025 4:34 PM] BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Report Preview: What to Expect [Apr-28-25 07:18PM] BEYONTTRA (acoramidis), the First Near-complete TTR Stabilizer ( 90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM [Apr-28-25 05:00AM] UK MHRA authorises BridgeBios acoramidis for ATTR-CM [2025-04-29 10:29AM] BridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential [2025-04-29 11:39AM] BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations [2025-04-29 04:01PM] BridgeBio Reports First Quarter 2025 Financial Results and Business Updates [2025-04-29 04:01PM] BridgeBio Pharma: Q1 Earnings Snapshot [2025-04-29 04:30PM] BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates [2025-04-29 05:35PM]
20-02-2025	PM		BBIO	BridgeBio Pharma	6,707	-1.31	-1.09	0.00	BridgeBio Pharma GAAP EPS of -$1.40, revenue of $5.9M [2/20/2025 7:38 AM]	36.79	0.50 (1.38%)	39.40	3.11 (8.57%)	21.62 - 39.47	6,362,611	2,350,000	270,114
BridgeBio Pharma GAAP EPS of -$1.40, revenue of $5.9M [2/20/2025 7:38 AM] BridgeBio Pharma Q4 2024 Earnings Preview [2/19/2025 1:34 PM] BridgeBio up 7% as Q4 revenue benefits from acoramidis prescriptions [2/20/2025 9:14 AM] BridgeBio Pharma: Q4 Earnings Snapshot [2025-02-20 07:49AM] BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update [2025-02-20 07:30AM]
12-11-2024	PM		BBIO	BridgeBio Pharma	5,094	-0.86	-1.03	0.00	BridgeBio Pharma GAAP EPS of -$0.86 beats by $0.09, revenue of $2.73M misses by $0.65M [11/12/2024 7:59 AM]	24.64	-1.48 (-5.67%)	25.81	-0.31 (-1.19%)	21.62 - 44.32	1,875,238	1,490,000	7,407
BridgeBio Pharma GAAP EPS of -$0.86 beats by $0.09, revenue of $2.73M misses by $0.65M [11/12/2024 7:59 AM] BridgeBio Pharma: Q3 Earnings Snapshot [2024-11-12 07:40AM] BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update [2024-11-12 07:30AM]
05-08-2021	PM		BBIO	Bridgebio Pharma, Inc.	7,881	-0.66	-0.93	0.00	BridgeBio Pharma EPS beats by $0.31, beats on revenue [8/5/2021 8:54 AM]	56.13	3.31 (6.26%)	52.83	0.0 (0.00%)	26.81 - 73.50	562,993	760,000	115,833
BridgeBio Pharma Q2 Earnings Preview [8/4/2021 10:52 AM] BridgeBio Pharma EPS beats by $0.31, beats on revenue [8/5/2021 8:54 AM] BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update [Aug-05-21 07:30AM] BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) [Aug-04-21 07:01PM] BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates [Aug-05-21 09:05AM]
06-05-2021	PM		BBIO	Bridgebio Pharma, Inc.	8,061	-1.18	-0.87	0.00	BridgeBio Pharma EPS misses by $0.37 [5/6/2021 8:01 AM]	49.59	-3.35 (-6.33%)	49.59	0.0 (0.00%)	26.17 - 73.50	1,543,727	540,000	1,186
BridgeBio Pharma EPS misses by $0.37 [5/6/2021 8:01 AM] BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update [May-06-21 07:30AM] BridgeBio Pharma (BBIO) Reports Q1 Loss, Lags Revenue Estimates [May-06-21 09:15AM]
05-11-2020	PM		BBIO	BridgeBio Pharma, Inc.	4,890	-0.98	-0.97	-0.51	BridgeBio Pharma EPS misses by $0.01, misses on revenue [11/5/2020 7:48 AM]	40.99	0.97 (2.42%)	40.99	0.0 (0.00%)	14.23 - 48.36	655,503	542,633	4,376

11-08-2020	PM	Before the open (Aug 11)	BBIO	BridgeBio Pharma, Inc.	3,460	-1.03	-0.79	0.00	BridgeBio Pharma EPS misses by $0.23 [8/11/2020 7:47 AM]	29.11	0.22 (0.76%)	28.89	0.0 (0.00%)	14.23 - 48.36	177,264	425,951	53,667